ProShares Ultra Nasdaq Biotechnology Rating → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free BIB Stock Alerts $49.66 +0.72 (+1.47%) (As of 04/26/2024 ET) Add Compare Share Share RatingsStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial MediaStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial Media ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy2.56Holdings in BIB have an aggregate rating of Moderate Buy based on 557 analyst ratings issued in the past year covering 43 companies (58.5% of the portfolio).BIB Aggregate Price Target$61.4223.68% UpsideHigh Prediction$80.42Average Prediction$61.42Low Prediction$44.65Holdings in BIB have an aggregate price target of $61.42 and a range of $44.65 to $80.42 covering 43 companies (58.5% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy6 Buy rating(s)Moderate Buy27 Moderate Buy rating(s)Hold9 Hold rating(s)Reduce0 Reduce rating(s)Sell1 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 43 BIB Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.33%AMGNAmgen$269.98+0.2%5 of 5 stars2.53$296.95 10.0%19Upcoming Earnings6.17%VRTXVertex Pharmaceuticals$397.48-0.1%4 of 5 stars2.48$429.45 8.0%236.11%REGNRegeneron Pharmaceuticals$883.20-0.8%5 of 5 stars2.70$977.77 10.7%20Upcoming EarningsAnalyst ReportAnalyst RevisionNews Coverage6.06%GILDGilead Sciences$65.42+0.2%5 of 5 stars2.35$83.87 28.2%17Earnings ReportDividend AnnouncementAnalyst UpgradeOptions VolumeAnalyst RevisionNews Coverage3.35%AZNAstraZeneca$75.17+0.2%2 of 5 stars2.57$81.00 7.8%7Analyst ReportShort Interest ↑Analyst RevisionNews Coverage3.28%MRNAModerna$107.97+1.7%4 of 5 stars2.25$126.49 17.1%16Upcoming EarningsInsider Selling2.33%BIIBBiogen$208.90+3.2%5 of 5 stars2.67$293.88 40.7%27Earnings ReportAnalyst ReportShort Interest ↓Analyst RevisionNews Coverage1.56%ILMNIllumina$122.28+1.0%5 of 5 stars2.32$167.70 37.1%19Upcoming Earnings1.54%ALNYAlnylam Pharmaceuticals$143.31-0.3%5 of 5 stars2.59$215.88 50.6%17Upcoming EarningsShort Interest ↓News Coverage1.43%BMRNBioMarin Pharmaceutical$80.91-1.5%5 of 5 stars2.63$107.50 32.9%19Analyst ReportOptions VolumeAnalyst RevisionNews Coverage1.11%NBIXNeurocrine Biosciences$135.99-1.3%5 of 5 stars2.74$142.38 4.7%23Upcoming EarningsAnalyst ReportShort Interest ↓Analyst RevisionNews Coverage1.11%VTRSViatris$11.57+0.9%0 of 5 stars1.33$11.00 -4.9%31.05%SNYSanofi$49.13-0.5%3 of 5 stars2.17$55.00 11.9%6Short Interest ↓Analyst RevisionNews Coverage1.05%RPRXRoyalty Pharma$28.00-0.4%5 of 5 stars3.00$46.75 67.0%4Positive News1.00%INCYIncyte$51.68+1.0%5 of 5 stars2.44$75.50 46.1%16Upcoming EarningsAnalyst ReportAnalyst Revision0.97%MEDPMedpace$395.93+1.6%5 of 5 stars2.80$443.00 11.9%5Earnings ReportAnalyst UpgradeAnalyst RevisionNews Coverage0.94%ARGXargenx$372.80+1.1%3 of 5 stars2.71$528.16 41.7%21Upcoming EarningsShort Interest ↑0.94%UTHRUnited Therapeutics$233.85-0.9%5 of 5 stars2.89$294.25 25.8%9Upcoming EarningsInsider Selling0.92%SRPTSarepta Therapeutics$128.77+1.1%4 of 5 stars2.79$156.60 21.6%14Analyst RevisionNews Coverage0.70%ROIVRoivant Sciences$11.03+1.4%4 of 5 stars2.90$16.90 53.2%10Short Interest ↑0.70%BNTXBioNTech$87.21+0.6%4 of 5 stars2.30$120.40 38.1%10News Coverage0.68%ASNDAscendis Pharma A/S$135.90-0.8%2 of 5 stars2.88$173.25 27.5%8Short Interest ↑News Coverage0.59%ITCIIntra-Cellular Therapies$73.26+1.6%4 of 5 stars2.90$90.17 23.1%10Upcoming EarningsAnalyst ReportAnalyst Revision0.58%CYTKCytokinetics$65.34+0.8%4 of 5 stars2.87$79.33 21.4%15Insider SellingShort Interest ↑News Coverage0.57%EXELExelixis$23.70+0.7%5 of 5 stars2.60$26.29 10.9%15Upcoming EarningsShort Interest ↑Analyst RevisionNews Coverage0.57%JAZZJazz Pharmaceuticals$109.46+1.9%5 of 5 stars2.85$195.08 78.2%13Upcoming EarningsNews Coverage0.55%PCVXVaxcyte$60.72+1.1%2 of 5 stars3.00$78.50 29.3%4Insider SellingNews Coverage0.50%RVMDRevolution Medicines$35.96+1.8%4 of 5 stars3.10$41.20 14.6%10Positive News0.50%IONSIonis Pharmaceuticals$41.59-0.6%4 of 5 stars2.69$56.08 34.8%13Upcoming Earnings0.48%APLSApellis Pharmaceuticals$49.86+4.0%4 of 5 stars2.87$77.93 56.3%15Analyst ReportAnalyst RevisionNews CoverageGap Up0.46%BGNEBeiGene$153.58+3.4%3 of 5 stars2.80$250.13 62.9%10Upcoming EarningsAnalyst ReportShort Interest ↑Analyst RevisionNews CoverageGap Up0.46%BPMCBlueprint Medicines$93.00+2.5%1 of 5 stars2.50$91.57 -1.5%14Upcoming EarningsAnalyst ReportNews CoverageGap Up0.40%HALOHalozyme Therapeutics$38.57+0.3%5 of 5 stars2.86$53.29 38.2%7Analyst RevisionNews Coverage0.39%KRYSKrystal Biotech$156.88+0.8%4 of 5 stars3.00$171.00 9.0%90.38%CRSPCRISPR Therapeutics$53.91+0.3%3 of 5 stars2.38$76.29 41.5%160.37%MDGLMadrigal Pharmaceuticals$193.33-0.5%5 of 5 stars2.73$356.73 84.5%110.37%BBIOBridgeBio Pharma$24.88+2.3%4 of 5 stars2.80$47.82 92.2%10Upcoming EarningsShort Interest ↑News Coverage0.36%ALPNAlpine Immune Sciences$64.56-0.1%2 of 5 stars2.27$50.33 -22.0%11Short Interest ↓0.35%IMVTImmunovant$27.17-2.1%3 of 5 stars3.00$48.00 76.7%17Insider SellingShort Interest ↓Analyst Revision0.33%ALKSAlkermes$24.68+1.0%5 of 5 stars2.50$35.38 43.3%10Upcoming EarningsShort Interest ↓0.32%LEGNLegend Biotech$45.30+2.0%2 of 5 stars2.92$82.64 82.4%12Analyst ReportGap Down0.31%NUVLNuvalent$66.86+1.2%3 of 5 stars2.90$90.78 35.8%10Insider Selling0.31%INSMInsmed$24.80-0.5%4 of 5 stars3.00$44.92 81.1%12Analyst ReportNews Coverage This page (NASDAQ:BIB) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
